old WP ej via Cision

  • Poster ESMO 2019

    Isofol Announces Presentation on the Global Phase 3 Study of arfolitixorin in Metastatic Colorectal Cancer at 2019 ESMO Congress GOTHENBURG,…

    by

  • Isofol Announces that an Abstract has been Accepted for Presentation at the 2019 ESMO Congress

    Isofol Announces that an Abstract has been Accepted for Presentation at the 2019 ESMO Congress GOTHENBURG, Sweden, September 12, 2019…

    by

  • Isofol Announces Management Team Evolution with Appointment of Dr. Roger Tell as Chief Medical Officer

    Isofol Announces Management Team Evolution with Appointment of Dr. Roger Tell as Chief Medical Officer GOTHENBURG, Sweden, August 15, 2019…

    by

  • Isofol Receives Clinical Use Patent Approval in the United States for Drug Candidate arfolitixorin

    Isofol Receives Clinical Use Patent Approval in the United States for Drug Candidate arfolitixorin GOTHENBURG, Sweden, June 25, 2019 –…

    by

  • Isofol Announces Election of Three New Board Members

    Isofol Announces Election of Three New Board Members GOTHENBURG, Sweden, June 10, 2019 – Isofol Medical AB (publ) (Nasdaq First…

    by

  • Isofol’s drug candidate arfolitixorin receives clinical patent approval in the United States

    Isofol’s drug candidate arfolitixorin receives clinical patent approval in the United States GOTHENBURG, Sweden, May 21, 2019 – Isofol Medical…

    by

  • Isofol Reports 58 % Overall Response Rate

    Isofol Reports 58 % Overall Response Rate in Patients with Metastatic Colorectal Cancer in Phase 1/2a Open Label Extension Study…

    by
  • aside

    Isofol Reports All Employees Participate in Newly Created Share Warrant Program

    GOTHENBURG, Sweden, February 1, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced that all senior…

    by
  • aside

    Isofol Reports Early Tumor Shrinkage in Patients with Colorectal Cancer in Phase 1/2a Open Label Extension Study with arfolitixorin

    GOTHENBURG, Sweden, January 17, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced positive results from…

    by
  • aside

    First patient enrolled in Isofol’s Pivotal Phase 3 AGENT study in 1st line metastatic colorectal cancer

    GOTHENBURG, Sweden, December 18, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced that the first…

    by